N. Curto-Garcia

发表

Bone marrow niche dysregulation in myeloproliferative neoplasms

C. Harrison, D. Mclornan, N. Curto-Garcia, 2020, Haematologica.

Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

K. Rezvani, C. Harrison, D. Mclornan, 2021, British journal of haematology.

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Blood Cancer Journal.

An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.

C. Harrison, N. Curto-Garcia, 2018, Future oncology.

Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK

C. Harrison, D. Mclornan, B. Hunt, 2020, British journal of haematology.

Long-term follow-up of recovered MPN patients with COVID-19

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Blood Cancer Journal.

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

C. Harrison, J. Kiladjian, J. Ianotto, 2019, Haematologica.

A team-based multidisciplinary approach to managing peripherally inserted central catheter complications in high-risk haematological patients: a prospective study

C. Burgaleta, J. García‐Suárez, N. Curto-Garcia, 2015, Supportive Care in Cancer.

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19

M. Griesshammer, T. Barbui, A. Patriarca, 2022, American journal of hematology.

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

M. Malim, D. Mclornan, C. Graham, 2021, British journal of haematology.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

M. Malim, C. Harrison, D. Mclornan, 2021, Leukemia.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML

M. Malim, D. Mclornan, C. Graham, 2021, medRxiv.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

M. Griesshammer, L. Shih, P. Cony-Makhoul, 2022, Blood advances.

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm

A. Mead, A. Godfrey, M. McMullin, 2021, Leukemia.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

M. Cazzola, T. Barbui, P. Guglielmelli, 2019, American journal of hematology.

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

D. Mclornan, H. de Lavallade, K. Raj, 2022, British journal of haematology.

Clinicopathological characterisation of myeloproliferative neoplasm‐unclassifiable (MPN‐U): a retrospective analysis from a large UK tertiary referral centre

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, British journal of haematology.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms

C. Harrison, D. Mclornan, D. Radia, 2017, British journal of haematology.

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, HemaSphere.

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Leukemia.

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

A. Mead, M. Salama, S. Verstovsek, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What is pre‐fibrotic myelofibrosis and how should it be managed in 2018?

C. Harrison, J. Ianotto, N. Curto-Garcia, 2018, British journal of haematology.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

A. Mead, J. Laurie, C. Yap, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Haematological emergencies

N. Curto-Garcia, J. Saunders, Andrew Doyle, 2022, Medicine.

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

M. Malim, D. Mclornan, K. Doores, 2022, Blood Cancer Journal.

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders

M. Malim, C. Harrison, D. Mclornan, 2022, Blood Advances.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms

C. Harrison, D. Mclornan, D. Radia, 2017, British Journal of Haematology.

Breakthrough infections in MPN-COVID vaccinated patients

M. Griesshammer, T. Barbui, A. Patriarca, 2022, Blood Cancer Journal.

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

M. Griesshammer, L. Shih, R. Skoda, 2023, Blood.